Showing results (41-50 of 71) with videos related to
Sort By:
Pageof 8
Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie|October 27, 2017
An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated CytotoxicityTim Wirt, Sophia Rosskopf, Thies Rösner, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 16, 2012
Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicityChristian Kellner, Tina Maurer, Daniela Hallack, et al.Mabs|February 5, 2014
Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2m(1) antibodyChristina Brunke, Stefan Lohse, Stefanie Derer, et al.The Journal of Biological Chemistry|June 9, 2012
Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophagesStefan Lohse, Christina Brunke, Stefanie Derer, et al.Journal of Clinical Medicine|July 2, 2021
Engineering of CD19 Antibodies: A CD19-TRAIL Fusion Construct Specifically Induces Apoptosis in B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Cells In VivoDorothee Winterberg, Lennart Lenk, Maren Oßwald, et al.Melanoma Research|March 14, 2008
A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cellsMichael Schwenkert, Katrin Birkholz, Michael Schwemmlein, et al.Blood|July 13, 2017
An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenograftsDenis M Schewe, Ameera Alsadeq, Cornelia Sattler, et al.Antibodies (Basel, Switzerland)|November 20, 2020
Enhancing CDC and ADCC of CD19 Antibodies by Combining Fc Protein-Engineering with Fc Glyco-EngineeringSophia Roßkopf, Klara Marie Eichholz, Dorothee Winterberg, et al.Oncoimmunology|March 5, 2016
Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30Christian Kellner, Andreas Günther, Andreas Humpe, et al.Frontiers in Immunology|September 2, 2022
Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumabNiklas Baumann, Christian Arndt, Judith Petersen, et al.Pageof 8